Cargando…

Swiss Medical Devices for Autologous Regenerative Medicine: From Innovation to Clinical Validation

Regenerative medicine, based on the use of autologous tissues and embryonic, stem or differentiated cells, is gaining growing interest. However, their preparation, in a manner compliant with good practices and health regulations, is a technical challenge. The aim of this manuscript is to present the...

Descripción completa

Detalles Bibliográficos
Autores principales: Gomri, Farid, Vischer, Solange, Turzi, Antoine, Berndt, Sarah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413293/
https://www.ncbi.nlm.nih.gov/pubmed/36015243
http://dx.doi.org/10.3390/pharmaceutics14081617
_version_ 1784775706912227328
author Gomri, Farid
Vischer, Solange
Turzi, Antoine
Berndt, Sarah
author_facet Gomri, Farid
Vischer, Solange
Turzi, Antoine
Berndt, Sarah
author_sort Gomri, Farid
collection PubMed
description Regenerative medicine, based on the use of autologous tissues and embryonic, stem or differentiated cells, is gaining growing interest. However, their preparation, in a manner compliant with good practices and health regulations, is a technical challenge. The aim of this manuscript is to present the design of reliable CE marked medical devices for the preparation of standardized platelet-rich plasma (PRP) and other autologous biologics intended for therapeutic uses. There are numerous PRP isolation processes. Depending on the methodology used, PRP composition varies greatly in terms of platelet concentration, platelet quality, and level of contamination with red and white blood cells. This variability in PRP composition might affect the clinical outcomes. The devices presented here are based on a specific technology, patented all over the world, that allows the precise separation of blood components as a function of their density using thixotropic separator gels in closed systems. This allows the preparation, in an automated manner, of leukocyte poor PRP with a standardized composition. Production of different forms of PRP is a clinical asset to suit various therapeutic needs. Therefore, we are offering solutions to prepare PRP either in liquid or gel form, and PRP combined with hyaluronic acid. These biologics have been successfully used in many different therapeutic domains, resulting in more than 150 published clinical studies. We also developed the CuteCell technology platform for cell culture expansion for further autologous cell therapies. This technology enables the safe and rapid in vitro expansion of cells intended for therapeutic use in good manufacturing practices (GMP) and autologous conditions, using blood-derived products as culture media supplementation. We summarize in this article our 20 years’ experience of research and development for the design of PRP devices and, more recently, for PRP combined with hyaluronic acid.
format Online
Article
Text
id pubmed-9413293
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94132932022-08-27 Swiss Medical Devices for Autologous Regenerative Medicine: From Innovation to Clinical Validation Gomri, Farid Vischer, Solange Turzi, Antoine Berndt, Sarah Pharmaceutics Review Regenerative medicine, based on the use of autologous tissues and embryonic, stem or differentiated cells, is gaining growing interest. However, their preparation, in a manner compliant with good practices and health regulations, is a technical challenge. The aim of this manuscript is to present the design of reliable CE marked medical devices for the preparation of standardized platelet-rich plasma (PRP) and other autologous biologics intended for therapeutic uses. There are numerous PRP isolation processes. Depending on the methodology used, PRP composition varies greatly in terms of platelet concentration, platelet quality, and level of contamination with red and white blood cells. This variability in PRP composition might affect the clinical outcomes. The devices presented here are based on a specific technology, patented all over the world, that allows the precise separation of blood components as a function of their density using thixotropic separator gels in closed systems. This allows the preparation, in an automated manner, of leukocyte poor PRP with a standardized composition. Production of different forms of PRP is a clinical asset to suit various therapeutic needs. Therefore, we are offering solutions to prepare PRP either in liquid or gel form, and PRP combined with hyaluronic acid. These biologics have been successfully used in many different therapeutic domains, resulting in more than 150 published clinical studies. We also developed the CuteCell technology platform for cell culture expansion for further autologous cell therapies. This technology enables the safe and rapid in vitro expansion of cells intended for therapeutic use in good manufacturing practices (GMP) and autologous conditions, using blood-derived products as culture media supplementation. We summarize in this article our 20 years’ experience of research and development for the design of PRP devices and, more recently, for PRP combined with hyaluronic acid. MDPI 2022-08-02 /pmc/articles/PMC9413293/ /pubmed/36015243 http://dx.doi.org/10.3390/pharmaceutics14081617 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Gomri, Farid
Vischer, Solange
Turzi, Antoine
Berndt, Sarah
Swiss Medical Devices for Autologous Regenerative Medicine: From Innovation to Clinical Validation
title Swiss Medical Devices for Autologous Regenerative Medicine: From Innovation to Clinical Validation
title_full Swiss Medical Devices for Autologous Regenerative Medicine: From Innovation to Clinical Validation
title_fullStr Swiss Medical Devices for Autologous Regenerative Medicine: From Innovation to Clinical Validation
title_full_unstemmed Swiss Medical Devices for Autologous Regenerative Medicine: From Innovation to Clinical Validation
title_short Swiss Medical Devices for Autologous Regenerative Medicine: From Innovation to Clinical Validation
title_sort swiss medical devices for autologous regenerative medicine: from innovation to clinical validation
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413293/
https://www.ncbi.nlm.nih.gov/pubmed/36015243
http://dx.doi.org/10.3390/pharmaceutics14081617
work_keys_str_mv AT gomrifarid swissmedicaldevicesforautologousregenerativemedicinefrominnovationtoclinicalvalidation
AT vischersolange swissmedicaldevicesforautologousregenerativemedicinefrominnovationtoclinicalvalidation
AT turziantoine swissmedicaldevicesforautologousregenerativemedicinefrominnovationtoclinicalvalidation
AT berndtsarah swissmedicaldevicesforautologousregenerativemedicinefrominnovationtoclinicalvalidation